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Abstract
purposE
To establish a consensus on clinical recommendation of oral supplementa-
tion for patients with or at risk of developing age-related macular degen-
eration (AmD), from the perspective of the Age-Related eye Disease Study 
2 (AReDS 2) and other studies. 
MEthods
Panel discussion based on a literature review of pertinent articles related to 
the prevention of AmD with oral supplementation. 
rEsults
on the basis of the findings, patients must first be encouraged to modify 
their diet and to eliminate modifiable risk factors before being recom-
mended any type of oral supplementation. Then, recommendations must 
be customized on the basis of a patient’s individual risk profile (i.e., age, 
gender, heredity, etc.) and severity of disease (i.e., category 1 to 4). essen-
tial fatty acids (omega-3s) and vitamins may play a role, in a given clinical 
population, to prevent the occurrence or the progression of AmD disease. 
However, there is no single formula that can be applied to all patients with 
or at risk of AmD. 
ConClusions
This group concluded that the full body of literature must be taken into 
consideration in order to justify clinical recommendations for patients. A 
single study such as AReDS 2 cannot, by itself, guide clinical practice. In 
all cases, recommendations must be individualized and patients should be 
monitored regularly.
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Age-related macular degeneration (AmD) is the leading cause of irreversible vision loss in developed countries.1,2 It is estimated that there are 17,000 new cases of neovascular (nv) AmD and 180,000 new cases of geographic atrophy (GA) AmD in Canada every 
year.3 The disease has a substantial negative impact on patient quality of life and imposes a 
considerable burden on the economy.3 early and intermediate stages of AmD are prevalent 
in people older than 65 years of age,4 and without intervention, the condition can evolve to 
advanced AmD5 and result in significant loss of visual function.
Published 12 years ago, the Age-Related eye Disease Study (AReDS) demonstrated that in 
persons with intermediate to severe AmD, a daily oral supplement containing vitamins and 
antioxidants reduced the risk of progression to advanced AmD by 25% versus placebo over 
a period of 5 years.6 This “AReDS formula” consisted of 500 milligrams (mg) vitamin C, 400 
international units (IU) of vitamin e, 15 mg beta-carotene, 80 mg zinc oxide, and 2 mg cupric 
oxide. Since then, observational studies have suggested that dietary intake of other carotenoids, 
particularly lutein and zeaxanthin, might play a role in protecting against AmD.7,8 moreover, the 
authors of AReDS9,10 and others8,11-13 highlighted the important role of dietary or supplemental 
forms of omega-3s, for preventing the development of AmD or its progression. 
This is the context in which the AReDS 2 was published in may 2013.14 This study, which 
was initiated in 2006, demonstrated that the addition of lutein, zeaxanthin, and omega-3s to 
the original AReDS formula, did not further reduce the risk of progression to advanced AmD 
sommaire
but
établir des recommandations cliniques consensuelles quant à la gestion clinique des patients 
atteints ou à risque de développer une dégénérescence maculaire liée à l’âge (DmLA). 
MÉthodEs
Discussion d’un panel d’experts basée sur l’analyse de divers articles scientifiques relatifs à la 
prise de suppléments vitaminiques et nutritionnels chez des patients atteints ou à risque de 
DmLA. 
rÉsultAts
Selon le panel, suite à l’analyse des articles, la première intervention devrait être d’inciter le 
patient à améliorer son hygiène de vie avant de recourir à des suppléments oraux. 
Par la suite, les recommandations cliniques doivent tenir compte du profil de risque du patient, 
de sa nutrition, de sa condition systémique ainsi que de l’état de sa santé oculaire. Les omégas 3s 
et les vitamines peuvent jouer un rôle bénéfique auprès de populations cibles afin de prévenir 
l’apparition ou l’évolution de la DmLA. Comme il n’existe pas de recettes uniques, le tout doit 
être personnalisé selon les besoins du patient. 
ConClusion
Le groupe conclut que l’ensemble de la littérature doit être prise en compte afin de justifier le 
recours à des suppléments oraux (omégas et vitamines) et que les recommandations doivent 
être personnalisées. Une seule étude, comme AReDS 2, bien que très importante, ne peut 
déterminer à elle-seule le comportement clinique des professionnels de la vue. L’importance du 
suivi régulier du patient doit également être comprise par tous.
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relative to the original formula.14 However, several secondary and subgroup analyses in this 
study suggested a benefit to replacing beta-carotene, which is associated with an increased 
risk of lung cancer in current and former smokers, with other carotenoids such as lutein and 
zeaxanthin. These conflicting results, notably with regard to omega-3s, have led to confusion 
among health care professionals about how to counsel patients and their caregivers about 
dietary strategies to prevent the development and progression of AmD. 
on november 1, 2013, a group of Quebec experts, consisting of eight optometrists and one 
ophthalmologist, gathered in montreal to discuss the outcomes of the AReDS 2 from a clinical 
perspective, with the goal of guiding the optimal management of this disease. In order to 
consider the AReDS 2 in a more global context, a general critique was undertaken. Then, each 
participant was assigned to review and present the key findings of a published article related to 
the use of dietary supplements or dietary factors associated with AmD (see Table 1 for a brief 
synopsis of the studies and key findings). A facilitated group discussion that ensued focused on 
synthesizing the data with the eventual goal of developing a clear and practical set of consensus-
based, nonbinding clinical recommendations for patients with AmD. 
gEnErAl CritiquE of thE ArEds 2 
First, it is important to recognize that the AReDS 2 was founded on the original AReDS. A 
socioeconomic analysis of the patients enrolled in this latter study showed that they were, on 
average, more educated and better nourished at baseline than the average American14 as well as 
those attending optometry practices in Canada. moreover, a substantial proportion of patients 
were already taking vitamin and antioxidant supplements,6,14 which suggested that their overall 
nutrition status was already supported by an external source of these nutrients. In this regard, 
there was no real placebo group in the AReDS 2. moreover, 14% of patients were additionally 
taking “nonauthorized” supplements, which further increased their antioxidant intake.14 
Furthermore, the dosage and formulation of omega-3 supplements that were used in this study 
(eicosapentaenoic acid greater than docosahexaenoic acid [ePA>DHA] 1000 mg/day versus 
2000 mg/day, as esters or triglycerides) were not optimal, considering the results of earlier 
studies on this subject. Finally, the AReDS 2 evaluated progression of AmD from moderate to 
advanced disease (nv and GA forms) without considering the effects of supplementation on the 
risk of development of the disease or its progression from mild to moderate disease.
The conclusions of the AReDS 2 can be applied to patients who were similar to those who 
were evaluated in the study, that is, patients with moderate to advanced AmD who are well 
nourished and well educated. Before extrapolating the study results to other patients, evidence 
derived from other studies must first be considered in order to appreciate the general context 
from which clinical recommendations can be formulated.
General reCommendationS
After considering the outcomes of several studies that were presented and keeping a general 
context in mind, a consensus was reached by this group of experts—that recommendations 
should be based on the individual patient and their particular risk profile. Health care 
professionals should assess a patient’s modifiable risk factors at the earliest opportunity to 
better counsel and categorize their risk of developing AmD or its progression to advanced AmD 
and to tailor advice about lifestyle, diet, and supplements. Tools are available to assist health 
care professionals in this regard. The results of the macular Assessment Program (mAP), which 
aimed at evaluating the perceptions versus the realities of 290 Canadian optometrists, were 
recently reported and reviewed at this meeting.15 This tool enables optometrists to categorize 
patients as having low, moderate, or high risk of AmD, on the basis of an evaluation of their 
modifiable and nonmodifiable risk factors. The literature suggests that the most important 
modifiable risk factors are smoking, alcohol consumption (>3 standard drinks/day), sun 
exposure (photostress), poor-quality diet, obesity, cardiovascular risk factors, and adherence to 
medication, whereas the most important nonmodifiable risk factors include age, gender, family 
history, ethnicity (Caucasians), and socioeconomic and educational status.
Therefore, all patients should be strongly encouraged to act on their modifiable risk factors 
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including smoking, diet, exercise, weight control, cholesterol, sun protection, and cardiovascular 
risk factors. This should constitute the foundation of counselling for all patients at risk of AmD 
or with AmD of any severity. Dietary advice should include information on food sources of 
lutein and zeaxanthin (e.g., green leafy vegetables and canned corn) and omega-3 fatty acids 
(e.g., wild fatty fish such as salmon, herring, and mackerel).
reCommendationS StemminG From tHe aredS 2
When a health care professional decides to recommend a vitamin supplement to a patient, 
the general consensus is that lutein and zeaxanthin should be preferred over beta-carotene. 
There is a growing body of evidence suggesting that high-dose beta-carotene supplementation 
(20–30 mg/day) is associated with a higher risk of lung cancer in smokers.14,16 The AReDS 
2 confirmed that any patient who actively smoked in the past must be considered a smoker, 
regardless of the duration since cessation. This is an important point because the prevalence 
of current and ex-smokers is higher in Quebec compared with the national average. According 
to the Canadian Tobacco Use monitoring Survey, in 2012, 14.9% of the Quebec population aged 
45 years and older identified themselves as current smokers and a further 44.7% were former 
smokers.17 
rECoMMEndAtions bAsEd on CAtEgory of AMd
primary prevention of amd
Among the group of experts of the AReDS 2, it was felt that unaffected people with risk factors 
for the disease (e.g., family history or genetic risk) had been less well studied in randomized 
controlled trials and that the potential benefits of supplementation with antioxidants remains 
unclear for them. However, strong evidence from observational studies suggests that diets 
rich in omega-3 fats and fish intake are associated with protection against the development 
of AmD.8,9,12,18 Consequently, eye health professionals may consider recommending omega-3 
supplements or a diet rich in omega-3 sources in patients with risk factors for AmD (e.g., 
genetics), especially those who are poorly nourished, rather than recommending antioxidant 
supplements. most of the experts also agreed that the safety and tolerability profile for 
omega-3 supplements was favourable and that supplementation did not appear to introduce 
unacceptable risks. There was stronger consensus among this group of experts that with regard 
to other modifiable risk factors, counselling that includes recommendation of regular exercise, 
sun protection, weight control, control of cardiovascular risk factors, and cessation of smoking, 
is very important and should not be neglected as a first step to prevent AmD occurrence. 
progression from early amd to advanced amd
The AReDS failed to demonstrate any significant benefit of supplementation in patients 
with less severe AmD (i.e., Category 1 or 2).6 In this study, very few patients with Category 
2 disease at baseline (i.e., patients with extensive small drusen, pigment abnormalities, or a 
few intermediate drusen) developed advanced AmD over the study period. on the basis of 
the available data, some clinicians therefore would not explicitly recommend antioxidant 
supplements to individuals with early AmD unless there was clear evidence of poor diet quality 
or dietary intake of carotenoids and omega-3s was insufficient. Dietary interventions may be of 
value in reducing the risk of progression in these patients.
intermediate or advanced amd 
For those patients who already have advanced AmD (i.e., defined by AReDS category), there 
may be some benefit in taking an antioxidant supplement with or without omega-3s, given that 
both the AReDS and the AReDS 2 showed a 25 to 30% reduction in the risk of progression 
from moderate to advanced AmD in the affected eye, as well as progression in the other eye.6,14 
Patients who are most likely to benefit from supplements are those who fit the profile of the 
patients studied in the AReDS and AReDS 2, that is, those with category 3 (many intermediate 
drusen or at least one large druse with abnormal pigmentation) or category 4 AmD (GA affecting 
the fovea or wet AmD with retinal fibrosis).14 
Some experts still believe that patients with intermediate or advanced AmD could also 
benefit from omega-3 fatty acid supplementation despite the negative findings of the AReDS 2,14 
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particularly older patients who often have comorbid conditions (cardiovascular disease, 
diabetes, etc.), in whom the beneficial effects of fatty acid supplementation have been more 
clearly demonstrated. However, at this time, given the available evidence from randomized 
controlled trials, the optimal dose of omega-3 supplements, duration of treatment, and the 
magnitude of potential benefit remain unclear. There is consistent evidence from observational 
studies that people who consume the highest amount of omega-3s, particularly in the form of 
triglycerides or fatty fish in their diet have a lower incidence of AmD or progression to advanced 
AmD compared with those with the lowest intake.9,12,18 moreover, supplementing the diet with 
omega-3s, through either diet or supplements, could offer ancillary benefits, notably in patients 
presenting with symptoms of dry eyes, which is often the case in patients with AmD.
It was acknowledged that many patients with AmD want to do something to try to 
improve their health and prevent the progression of their disease. Taking a supplement that 
offers a potential 25% reduction in the risk of progression6 may offer them hope and a sense 
of control over their disease. notably, evidence suggests that people with the lowest dietary 
intakes of antioxidants14 and those under 75 years of age7 may derive the greatest benefits 
from supplementation. These patients might therefore constitute the best group to target in 
terms of clinical recommendations around diet and supplements. This further underscores 
the importance of classifying patients according to their risk of advanced AmD in the clinical 
setting.
should wE rECoMMEnd supplEMEnts vErsus diEtAry intErvEntions?
This group of experts acknowledged that patients must first be counselled to modify their 
diet to include green vegetables (source of lutein and zeaxanthin), and carotenoids and vitamins 
(fruits and vegetables), as well as fatty fish, if possible from wild sources, several times a 
week. For example, some studies reported benefits of consuming four or more portions of fish 
weekly.18 In addition to the quantity of fish, the type of fish may also be influential with respect 
to outcomes.12 moreover, clinicians should be cognizant of the tendency of patients to over-
report or overstate adherence to dietary recommendations. The populations studied tended 
to be better nourished and more highly educated than the general population, particularly in 
the AReDS6 and the AReDS 2.14 This might have biased the results of studies. Consequently, 
it seems logical to recommend supplements to people with nutritional deficiencies and risk 
factors for AmD, as well as for people living alone (who are often less well nourished) in the 
hope that outcomes will be superior to those expected in well-nourished patients.
once supplementation is recommended, it is essential to assess adherence during follow-
up visits. one should not assume that patients are always adherent to their prescribed 
regimen. Factors that may limit patient adherence to dietary supplementation include lack 
of perceived benefit (e.g., no effects on vision), cost of supplements, size of pills, frequency of 
dosing, and potential problems with tolerability (e.g., gastrointestinal discomfort). eye care 
professionals should be prepared to discuss the reasons for recommending supplements and 
help their patients set reasonable goals. From the start, it should be made clear to patients that 
supplements do not improve vision but that they are meant to reduce the risk of progression to 
more advanced disease. The AReDS suggested that in patients with category 3 or 4 AmD who 
are generally well nourished, the risk of progression to advanced disease may be reduced by 25 
to 30% with antioxidant supplementation.6 
inforMAtion for othEr hEAlth CArE profEssionAls
vitamin and nutritional supplements can have an impact on a patient’s medication regimen. 
When in doubt, eye care professionals should seek advice from the pharmacist to better evaluate 
the risk of potential drug–nutrient interactions. Although there have been some concerns about 
the use of supplements in patients with existing renal dysfunction, in the clinical experience of 
this group of advisors, such problems have been uncommon. Patients should also be reminded 
to inform their family physician about any intake of vitamins or omega-3s, notably when taking 
other medications such as warfarin or antidiabetic drugs, since the dosage of these might need 
to be adjusted based on the patient’s response to omega-3s.
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rECoMMEndAtions for optiMAl frEquEnCy of follow-up
Timing of follow-up is an important consideration because the optometrist needs to 
see the intermediate AmD patient at the right time to see progression of the disease. Like 
recommendations for supplements and diet, the frequency of follow-up should ideally be 
individualized to the patient’s risk profile and needs. It was generally agreed that patients with 
milder cases of AmD (i.e., category 2 or lower) should be seen at least annually. The majority of 
patients with category 3 AmD should be monitored every 6 months and, in some cases, more 
often. Patients with nv AmD should be seen more frequently by their ophthalmologist (i.e., 
three or four times annually). Self-report of symptoms using the Amsler grid does not substitute 
for clinic visits, although it can complement the tools used for assessing the progression of 
disease. Finally, clinical visits represent an opportunity for optometrists to educate patients 
about modifiable risk factors, the importance of following clinical recommendations, and to 
modify the treatment and follow-up plan as needed. 
EXAMinAtion of thE pAtiEnt with AMd
In a perfect world, optical coherence tomography (oCT) would be used to test all patients with 
AmD to monitor for progression to neovascular disease. However, given the limited resources, 
judicious use is of this technology is necessary. It was suggested that a baseline oCT followed 
by annual testing might be appropriate in Category 3 or 4 patients with no new symptoms or 
complaints and without evidence of hemorrhage or exudate on clinical examination. oCT is not 
mandatory but is recommended in patients with dry AmD, especially if a visual acuity change 
occurs. Fundus photography is a good tool to document a patient’s status and allow for easy 
evaluation of a patient’s disease progression. In addition, it can be beneficial to show patients 
pictures of their eye examination, results of oCT, or both to help them understand their disease 
and its eventual progression and thereby promote greater adherence to the proposed treatment 
regimen. 
For patients with category 1 or 2 AmD, use of the Amsler grid remains appropriate despite 
suboptimal sensitivity and specificity. This at-home test is particularly helpful for patients to 
self-evaluate the progression of their eye disease. optometrists must remember to instruct 
patients to test one eye at a time. 
ConClusion
The first step in the management of a patient with AmD is to identify the disease and 
determine its severity. Recommendations must be customized based on a patient’s individual 
risk profile (i.e., age, gender, heredity, etc.) and severity of disease (i.e., category 1 to 4). There is 
no single formula that can be applied to all patients with or at risk of AmD. 
Patients must, first and foremost, be encouraged to modify their diet and to eliminate 
modifiable risk factors such as smoking, sedentary lifestyle, excessive alcohol intake, and 
so on. The patient should be encouraged to exercise regularly. medication adherence (for 
hypertension, hypercholesterolemia, diabetes, etc.) must be reinforced. Taking a supplement 
must not be a substitute for making healthy lifestyle changes.
next, the optometrist should ensure that the patient’s eyeware provides adequate protection 
against ultraviolet rays. evidence to date supports the use of a daily high-dose antioxidant 
supplement consisting of vitamins C and e, carotenoids, and zinc (i.e., the AReDS 2 formula), 
to reduce the risk of progression from intermediate to advanced AmD. optometrists should 
recommend this type of supplement to patients with category 3 or 4 AmD to mitigate the risk 
of disease progression. The benefits in patients with milder forms of AmD or in those who are 
at risk of developing the disease is less clear. In such cases, it could be beneficial to recommend 
an omega-3 supplement, and eventually vitamin supplements, based on the patient’s diet 
quality. The results of observational studies, including those derived from the original AReDS 
study, suggest that omega-3 supplementation may help to prevent or slow the progression of 
disease in its early stage. This approach has biological plausibility, since omega-3 fatty acids are 
concentrated in the retina and have been shown to modulate retinal function.
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on the basis of the recently reported AReDS 2 study, substitution of beta-carotene by lutein 
plus zeaxanthin seems reasonable, since these carotenoids have been shown to protect against 
AmD without the associated risk of lung cancer in smokers. Consequently, any patient who 
has previously been a smoker or been exposed to second-hand smoke should consider taking 
supplements that do not contain beta-carotene. 
This group concluded that the full body of literature must be taken into consideration in 
order to justify clinical recommendations for patients. A single study cannot, by itself, guide 
clinical practice. In all cases, recommendations must be individualized and patients should be 
monitored regularly.
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